Source: United States & Canada – South China Morning PostPfizer Inc. and partner BioNTech SE said their Covid-19 vaccine was safe and produced strong antibody responses in children ages five to 11 in a large-scale trial, findings that could pave the way to begin vaccinating grade-school kids within months.The long-awaited results offer one of the first looks at how well a Covid-19 vaccine could work for younger children. Pressure to immunise kids has been on the rise in the US, where a new school year has started just as the Delta variant is fuelling…Read More